Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velcade and Alimta in Advanced NSCLC
NCT00343720Phase 2Completed
- Sponsor
- Millennium Pharmaceuticals
- Primary completion
- Oct 2007
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bortezomib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Millennium Pharmaceuticals. Primary endpoint: Objective Response Rate. Status: completed.
02
Drugs
bortezomib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00343720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00343720.